Panacea Biotec Limited has informed the Exchange regarding 'Nation-Wide Study Confirms ChilRun full Accelerates Growth and Development in Children, in just 90 days'.
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Panacea Biotec's material subsidiary, Panacea Biotec Pharma Limited, shared results of a 90-day nationwide post-marketing observational study on its oral nutritional supplement, ChilRun full. The study covered 2,851 children aged 2+ years across 282 clinics in 32 Indian cities. Key findings include significant improvements in height, weight, and BMI, with up to 20.56% weight gain observed in undernourished children. The product contains 37 essential nutrients and is sold through online platforms like Amazon, Flipkart, and Tata 1mg. The Managing Director of PBPL called ChilRun full a transformative tool in pediatric nutrition and in the fight against malnutrition.
This is a product marketing/PR announcement supporting the efficacy of an existing nutritional supplement, with no direct financial figures or material business impact disclosed. It may modestly boost the visibility of Panacea Biotec's nutrition portfolio but is unlikely to move the stock meaningfully on its own.